Can a tiny dose of IL-2 tame hay fever?
NCT ID NCT03776643
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether a low dose of IL-2 (a protein that helps regulate the immune system) could reduce nasal symptoms in people with birch pollen allergy. Twenty-four adults with a history of seasonal allergies received either the drug or a placebo over several months. The goal was to see if the treatment could calm the allergic response during controlled pollen exposure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ILT-101 (low-dose interleukin-2)
- What this could lead to
- If it works, this could point toward a new way to manage seasonal allergies by boosting the body's own immune regulation.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. The treatment is still experimental and may not provide significant symptom relief.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINOCONJUNCTIVITIS TO BIRCH POLLEN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CIC Biothérapies - Service de Biothérapies
Paris, Groupe Hospitalier Pitié-Salpêtrière 47 -83 BD de L'hopital, 75013, France
-
Centre d'essais cliniques, ALYATEC
Strasbourg, Environmental Exposure Chamber, Alyatec, 1 Place de L'hôpital, 67000, France